NasdaqGM - Delayed Quote USD

Revance Therapeutics, Inc. (RVNC)

3.4000 +0.1100 (+3.34%)
At close: April 26 at 4:00 PM EDT
3.4000 0.00 (0.00%)
After hours: April 26 at 4:20 PM EDT
Currency in USD All numbers in thousands
Download
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Total Revenue
234,040.0000
234,040.0000
132,565.0000
77,798.0000
15,325.0000
Cost of Revenue
74,363.0000
74,363.0000
51,667.0000
23,410.0000
4,769.0000
Gross Profit
159,677.0000
159,677.0000
80,898.0000
54,388.0000
10,556.0000
Operating Expense
382,012.0000
382,012.0000
353,067.0000
329,064.0000
283,718.0000
Operating Income
-222,335.0000
-222,335.0000
-272,169.0000
-274,676.0000
-273,162.0000
Net Non Operating Interest Income Expense
-6,071.0000
-6,071.0000
-11,583.0000
-5,936.0000
-10,826.0000
Other Income Expense
-95,280.0000
-95,280.0000
-71,970.0000
-698.0000
-721.0000
Pretax Income
-323,686.0000
-323,686.0000
-355,722.0000
-281,310.0000
-284,709.0000
Tax Provision
300.0000
300.0000
700.0000
--
-2,620.0000
Net Income Common Stockholders
-323,986.0000
-323,986.0000
-356,422.0000
-281,310.0000
-282,089.0000
Diluted NI Available to Com Stockholders
-323,986.0000
-323,986.0000
-356,422.0000
-281,310.0000
-282,089.0000
Basic EPS
-3.83
-3.83
-4.90
-4.17
-4.86
Diluted EPS
-3.83
-3.83
-4.90
-4.17
-4.86
Basic Average Shares
84,599.4090
84,599.4090
72,713.3400
67,507.8180
58,009.1620
Diluted Average Shares
84,599.4090
84,599.4090
72,713.3400
67,507.8180
58,009.1620
Total Operating Income as Reported
-316,777.0000
-316,777.0000
-341,958.0000
-274,676.0000
-273,162.0000
Total Expenses
456,375.0000
456,375.0000
404,734.0000
352,474.0000
288,487.0000
Net Income from Continuing & Discontinued Operation
-323,986.0000
-323,986.0000
-356,422.0000
-281,310.0000
-282,089.0000
Normalized Income
-249,376.8200
-249,376.8200
-301,288.6900
-281,310.0000
-282,089.0000
Interest Income
13,285.0000
13,285.0000
4,891.0000
337.0000
4,322.0000
Interest Expense
19,356.0000
19,356.0000
16,474.0000
6,273.0000
15,148.0000
Net Interest Income
-6,071.0000
-6,071.0000
-11,583.0000
-5,936.0000
-10,826.0000
EBIT
-304,330.0000
-304,330.0000
-339,248.0000
-275,037.0000
-269,561.0000
EBITDA
-290,637.0000
-290,637.0000
-300,102.0000
-255,184.0000
-259,311.0000
Reconciled Cost of Revenue
71,034.0000
71,034.0000
44,606.0000
17,545.0000
596.0000
Reconciled Depreciation
13,693.0000
13,693.0000
39,146.0000
19,853.0000
10,250.0000
Net Income from Continuing Operation Net Minority Interest
-323,986.0000
-323,986.0000
-356,422.0000
-281,310.0000
-282,089.0000
Total Unusual Items Excluding Goodwill
-94,442.0000
-94,442.0000
-69,789.0000
--
--
Total Unusual Items
-94,442.0000
-94,442.0000
-69,789.0000
--
--
Normalized EBITDA
-196,195.0000
-196,195.0000
-230,313.0000
-255,184.0000
-259,311.0000
Tax Rate for Calcs
0.0002
0.0002
0.0002
--
0.0000
Tax Effect of Unusual Items
-19,832.8200
-19,832.8200
-14,655.6900
--
--
12/31/2020 - 2/6/2014

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

AMLX Amylyx Pharmaceuticals, Inc.
1.7600
-1.12%
 
DAWN Day One Biopharmaceuticals, Inc.
14.92
+12.94%
 
FATE Fate Therapeutics, Inc.
3.8000
-1.81%
 
SAGE Sage Therapeutics, Inc.
13.69
+0.81%
 
KPTI Karyopharm Therapeutics Inc.
1.0600
0.00%
 
ARQT Arcutis Biotherapeutics, Inc.
8.47
-1.40%
 
PTCT PTC Therapeutics, Inc.
28.57
+12.08%
 
ABEO Abeona Therapeutics Inc.
3.2600
+2.19%
 
TSVT 2seventy bio, Inc.
4.2550
-0.82%
 
TVTX Travere Therapeutics, Inc.
5.26
-2.41%